18642-23-4
基本信息
补骨酯定
补骨脂啶
补骨脂定对照品
补骨脂定, BR
补骨脂定(标准品)
PSORALIDIN 补骨脂定
PSORALIDIN 补骨脂定 标准品
3,9-二羟基-2-(3-甲基丁-2-烯-1-基)-6H-苯并呋喃并[3,2-C]苯并吡喃-6-酮
psoralidin
Psoralidin, BR
Psoralidin, >=99%
3,9-Dihydroxy-2-prenylcoumestan
3,9-dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one
3,9-Dihydroxy-2-(3-methylbut-2-en-1-yl)-6H-benzofuro[3,2-c]chromen-6-one
3,9-Dihydroxy-2-(3-methyl-2-butenyl)-6H-benzofuro[3,2-c][1]benzopyran-6-one
6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)-
物理化学性质
| 外观性状 | 淡黄色结晶粉末,可溶于甲醇、乙醇、DMSO等有机溶剂,来源于补骨脂Psoralea corylifolia Linn.种子。 |
| 熔点 | 290-292° |
| 沸点 | 458.8±34.0 °C(Predicted) |
| 密度 | 1.383±0.06 g/cm3(Predicted) |
| 储存条件 | ?20°C |
| 溶解度 | DMSO:可溶5mg/mL,澄清(加热) |
| 酸度系数(pKa) | 8.70±0.20(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChI | 1S/C20H16O5/c1-10(2)3-4-11-7-14-17(9-15(11)22)25-20(23)18-13-6-5-12(21)8-16(13)24-19(14)18/h3,5-9,21-22H,4H2,1-2H3 |
| InChIKey | YABIJLLNNFURIJ-UHFFFAOYSA-N |
| SMILES | CC(C)=CCC1=C(C=C(OC2=O)C(C(OC3=C4)=C2C3=CC=C4O)=C1)O |
安全数据
| 危险性符号(GHS) | ![]() GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302 |
| 防范说明 | P301+P312+P330 |
| WGK Germany | 3 |
| 海关编码 | 2932.20.4500 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Acute Tox. 4 Oral |
补骨脂定价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-N0232 | 补骨脂定 Psoralidin | 18642-23-4 | 5mg | 600元 |
| 2025/12/22 | HY-N0232 | 补骨脂定 Psoralidin | 18642-23-4 | 10 mM * 1 mLin DMSO | 660元 |
| 2025/12/22 | HY-N0232 | 补骨脂定 Psoralidin | 18642-23-4 | 10mg | 960元 |
常见问题列表
|
COX-2
|
5-LOX
|
Three breast cancer cell (BCC)populations (ALDH
-
cells, ALDH
+
cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC
50
s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin.
Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH
-
cells, ALDH
+
cells, and commercial BCSCs.
Psoralidin treatment also downregulates NOTCH1 expression in both ALDH
-
and ALDH
+
cells.
Cell Viability Assay
| Cell Line: | ALDH - cells, ALDH + cells, commercial breast cancer stem cells (BSCSs), and normal breast epithelial cells (MCF-12A) |
| Concentration: | 10, 15, 50, and 25 μM |
| Incubation Time: | 24 hours |
| Result: | IC 50 s of 18 to 21 μM for ALDH - cells, ALDH + cells, commercial BCSCs. |
Apoptosis Analysis
| Cell Line: | ALDH - cells, ALDH + cells, and commercial BCSCs |
| Concentration: | 20 and 30 μM |
| Incubation Time: | 24 hours |
| Result: | No significant induction of apoptosis was observed for any of the three cell types following treatment at 20 μM. However, 53.60%, 44.1%, and 45.9% of cells were apoptotic at 30 μMin ALDH - cells, ALDH + cells, and commercial BCSCs, respectively. |
Psoralidin (5 mg/kg) regulates expression of pro-inflammatory cytokines that play an important role in inflammatory diseasesin IR-irradiated lung of BALB/c mouse.
| Animal Model: | BALB/c mice |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal application; 30 min before and 1 h after IR irradiation (20 Gy). |
| Result: | Anti-inflammatory effect in IR-irradiated mice. |
